USF among top 10 organizations worldwide with 15 Fellows named this year

USF Health researchers comprised a third (5) of the record number of University of South Florida faculty members elected 2012 Fellows of the American Association for the Advancement of Science (AAAS). 

The 15 faculty members from USF awarded the prestigious honor — up from four last year – catapulted USF into the top 10 institutions worldwide with the most AAS Fellows named this year.  The lifetime designation recognizes scientifically or socially distinguished efforts to advance science or its applications.

The five USF Health faculty members – representing the Morsani College of Medicine, College of Public Health and College of Pharmacy – named AAAS Fellows this year are:

Paula C. Bickford, PhD, professor of Neurosurgery and Brain Repair and senior research career scientist at James A. Haley Veterans’ Hospital:  For distinguished contributions to the field of aging research, and particularly as a leader in the field of nutritional neuroscience and for outstanding service.

Cesar V. Borlongan, PhD, professor and vice chair for research in Neurosurgery and Brain Repair:   For distinguished contributions to the field of stem cell therapy for neurological disorders, particularly for advancing translational biomedical research of cell based-therapeutics in stroke.

Robert J. Deschenes, PhD, professor and chair of Molecular Medicine:  For distinguished contributions to the field of molecular cell biology and the use of model genetic systems to elucidate the spatial arrangement of signaling proteins. 

Karen D. Liller, PhD, professor of Community and Family Health, dean of the USF Graduate School, and associate vice president for Research and Innovation:  For distinguished contributions as a graduate education administrator and also as a research scholar in the fields of public health and children’s injury prevention.

Lynn Wecker, PhD, Distinguished University Professor of Psychiatry and Behavioral Neuroscience and Distinguished Research Professor:   For distinguished service to the scientific community as an innovative, highly accomplished researcher, award-winning teacher, and dedicated servant and leader of her academic disciplines.

For more  information, go to the USF News Page.

Five of the record-breaking 15 faculty members from USF named 2012 AAAS Fellows are from USF Health.

A nicotinic drug approved for smoking cessation significantly improved the walking ability of patients suffering from an inherited form of ataxia, reports a new clinical study led by University of South Florida researchers.

The randomized controlled clinical trial investigated the effectiveness of varenicline (Chantix®) in treating spinocerebellar ataxia type 3, or SCA3. The findings were published online earlier this month in Neurology, the journal of the American Academy of Neuroscience. Lead author Dr. Theresa Zesiewicz and colleagues at the USF Ataxia Research Center collaborated with researchers from Beth Israel Deaconess Medical Center in Boston, MA, and from the David Geffen School of Medicine at UCLA in Los Angeles, CA.

Spinocerebellar ataxia impairs the brain and spinal cord causing progressive difficulty with coordination of movements, including walking. The uncoordinated movements, or ataxia, is a neurological symptom with no treatment or cure and can lead to serious fall-related injuries.

Principal investigator Theresa Zesiewicz, MD

“This is the first clinical trial in patients with ataxia showing that nicotinic acetycholine agonists improve symptoms associated with the ability to stand straight and walk,” said Dr. Zesiewicz, professor of neurology and director of the USF Ataxia Research Center. “Patients receiving varenicline could walk with more ease, with less help and faster than those in the placebo group.”

The double-blind multicenter study evaluated 20 adult patients with genetically confirmed SCA3. Half the patients received 1 mg. of varenicline twice a day, and the other half received placebo. At the end of the eight-week study, patients taking varenecline performed significantly better on measures of gait, stance, rapid alternating movements and a timed 25-foot walk than those who did not. The drug was fairly well tolerated, with mild nausea being the most common side effect.

The study authors suggest that varenicline’s ability to improve ataxia may be associated with the drug’s ability to act at several different sites in the brain affected by nicotine.

Study co-author Lynn Wecker, PhD, a distinguished research professor at USF Health, is investigating the cellular and molecular mechanisms mediating the effects of varenicline and other nicotinic agonists. Dr. Wecker and colleagues, supported by a five-year grant funded by the National Institute of Neurological Disorders and Stroke, have shown that several drugs affecting neuronal nicotinic receptors improve gait and balance in an animal model of SCA3.

Lynn Wecker, PhD, study co-author

Further preclinical research is needed to understand how nicotinic acetylcholine agonists improve ataxia, and larger clinical studies with more patients are needed to identify other neurodegenerative diseases that may benefit from nicotinic medications, the authors conclude.

The study was supported by the National Ataxia Foundation; the Bobby Allison Ataxia Research Center; Nancy Scheid, executive board member of the USF ARC; and George Ramsay, whose son Ed Ramsay is a board member.

Citation: “A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3,”T.A. Zesiewicz, MD, FAAN; P.E. Greenstein, MB, BCh; K.L. Sullivan, MSPH; L. Wecker, PhD; A. Miller, BS; I. Jahan, MD; R. Chen, MD and S.L. Perlman, MD, FAAN, Neurology, published online before print Feb. 8, 2012. DOI: 10.1212/WNL.0b013e318247cc7a.

Story by Anne DeLotto Baier, USF Health Communications